25 XP   0   0   10

MaxCyte Inc
Buy, Hold or Sell?

Let's analyse Maxcyte together

PenkeI guess you are interested in MaxCyte Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of MaxCyte Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about MaxCyte Inc

I send you an email if I find something interesting about MaxCyte Inc.

Quick analysis of Maxcyte (30 sec.)










What can you expect buying and holding a share of Maxcyte? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.23
Expected worth in 1 year
$2.02
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-0.21
Return On Investment
-5.0%

For what price can you sell your share?

Current Price per Share
$4.19
Expected price per share
$3.25 - $5.29
How sure are you?
50%

1. Valuation of Maxcyte (5 min.)




Live pricePrice per Share (EOD)

$4.19

Intrinsic Value Per Share

$-0.72 - $-0.76

Total Value Per Share

$1.51 - $1.47

2. Growth of Maxcyte (5 min.)




Is Maxcyte growing?

Current yearPrevious yearGrowGrow %
How rich?$232.1m$256.9m-$18.3m-7.7%

How much money is Maxcyte making?

Current yearPrevious yearGrowGrow %
Making money-$8.9m-$4.9m-$3.9m-44.5%
Net Profit Margin-97.7%-46.7%--

How much money comes from the company's main activities?

3. Financial Health of Maxcyte (5 min.)




4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  


Richest
#98 / 340

Most Revenue
#189 / 340

Most Profit
#261 / 340

Most Efficient
#243 / 340

What can you expect buying and holding a share of Maxcyte? (5 min.)

Welcome investor! Maxcyte's management wants to use your money to grow the business. In return you get a share of Maxcyte.

What can you expect buying and holding a share of Maxcyte?

First you should know what it really means to hold a share of Maxcyte. And how you can make/lose money.

Speculation

The Price per Share of Maxcyte is $4.19. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Maxcyte.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Maxcyte, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.23. Based on the TTM, the Book Value Change Per Share is $-0.05 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Maxcyte.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.05-1.2%-0.09-2.2%-0.06-1.4%-0.06-1.4%-0.06-1.4%
Usd Book Value Change Per Share-0.01-0.3%-0.05-1.2%-0.02-0.5%0.153.5%0.153.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-0.3%-0.05-1.2%-0.02-0.5%0.153.5%0.153.5%
Usd Price Per Share4.70-4.34-5.92-4.23-4.23-
Price to Earnings Ratio-23.19--13.40--28.87--22.81--22.81-
Price-to-Total Gains Ratio-404.64--150.27--646.58--405.11--405.11-
Price to Book Ratio2.11-1.89-2.40-1.73-1.73-
Price-to-Total Gains Ratio-404.64--150.27--646.58--405.11--405.11-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.19
Number of shares238
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.050.15
Usd Total Gains Per Share-0.050.15
Gains per Quarter (238 shares)-12.4635.38
Gains per Year (238 shares)-49.83141.51
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-50-600142132
20-100-1100283274
30-149-1600425416
40-199-2100566558
50-249-2600708700
60-299-3100849842
70-349-3600991984
80-399-410011321126
90-448-460012741268
100-498-510014151410

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.015.00.00.0%0.015.00.00.0%0.015.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.09.01.016.7%3.010.02.020.0%3.010.02.020.0%3.010.02.020.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.015.00.0%0.00.015.00.0%0.00.015.00.0%
Total Gains per Share0.04.00.00.0%2.09.01.016.7%3.010.02.020.0%3.010.02.020.0%3.010.02.020.0%

Fundamentals of Maxcyte

About MaxCyte Inc

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Fundamental data was last updated by Penke on 2024-03-21 00:43:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of MaxCyte Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Maxcyte earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Maxcyte to the Medical Devices industry mean.
  • A Net Profit Margin of -33.7% means that $-0.34 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of MaxCyte Inc:

  • The MRQ is -33.7%. The company is making a huge loss. -2
  • The TTM is -97.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-33.7%TTM-97.7%+64.0%
TTM-97.7%YOY-46.7%-50.9%
TTM-97.7%5Y-63.9%-33.7%
5Y-63.9%10Y-63.9%0.0%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-33.7%-10.6%-23.1%
TTM-97.7%-20.2%-77.5%
YOY-46.7%-14.0%-32.7%
5Y-63.9%-19.5%-44.4%
10Y-63.9%-23.8%-40.1%
1.1.2. Return on Assets

Shows how efficient Maxcyte is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Maxcyte to the Medical Devices industry mean.
  • -2.0% Return on Assets means that Maxcyte generated $-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of MaxCyte Inc:

  • The MRQ is -2.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.0%TTM-3.3%+1.3%
TTM-3.3%YOY-1.7%-1.6%
TTM-3.3%5Y-3.8%+0.6%
5Y-3.8%10Y-3.8%0.0%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.0%-3.0%+1.0%
TTM-3.3%-4.2%+0.9%
YOY-1.7%-4.0%+2.3%
5Y-3.8%-3.8%0.0%
10Y-3.8%-4.1%+0.3%
1.1.3. Return on Equity

Shows how efficient Maxcyte is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Maxcyte to the Medical Devices industry mean.
  • -2.3% Return on Equity means Maxcyte generated $-0.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of MaxCyte Inc:

  • The MRQ is -2.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -3.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.3%TTM-3.7%+1.5%
TTM-3.7%YOY-1.9%-1.8%
TTM-3.7%5Y-5.1%+1.4%
5Y-5.1%10Y-5.1%0.0%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.3%-3.5%+1.2%
TTM-3.7%-4.4%+0.7%
YOY-1.9%-4.7%+2.8%
5Y-5.1%-5.7%+0.6%
10Y-5.1%-6.2%+1.1%

1.2. Operating Efficiency of MaxCyte Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Maxcyte is operating .

  • Measures how much profit Maxcyte makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Maxcyte to the Medical Devices industry mean.
  • An Operating Margin of -51.6% means the company generated $-0.52  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of MaxCyte Inc:

  • The MRQ is -51.6%. The company is operating very inefficient. -2
  • The TTM is -131.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-51.6%TTM-131.0%+79.5%
TTM-131.0%YOY-63.4%-67.6%
TTM-131.0%5Y-75.6%-55.4%
5Y-75.6%10Y-75.6%0.0%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-51.6%-24.5%-27.1%
TTM-131.0%-14.9%-116.1%
YOY-63.4%-11.5%-51.9%
5Y-75.6%-17.1%-58.5%
10Y-75.6%-20.6%-55.0%
1.2.2. Operating Ratio

Measures how efficient Maxcyte is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 1.52 means that the operating costs are $1.52 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of MaxCyte Inc:

  • The MRQ is 1.516. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.310. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.516TTM2.310-0.795
TTM2.310YOY1.634+0.676
TTM2.3105Y1.757+0.553
5Y1.75710Y1.7570.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5161.454+0.062
TTM2.3101.452+0.858
YOY1.6341.434+0.200
5Y1.7571.432+0.325
10Y1.7571.366+0.391

1.3. Liquidity of MaxCyte Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Maxcyte is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 10.65 means the company has $10.65 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of MaxCyte Inc:

  • The MRQ is 10.652. The company is very able to pay all its short-term debts. +2
  • The TTM is 14.064. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ10.652TTM14.064-3.412
TTM14.064YOY15.684-1.620
TTM14.0645Y12.342+1.722
5Y12.34210Y12.3420.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ10.6522.789+7.863
TTM14.0642.793+11.271
YOY15.6843.586+12.098
5Y12.3423.492+8.850
10Y12.3423.450+8.892
1.3.2. Quick Ratio

Measures if Maxcyte is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Maxcyte to the Medical Devices industry mean.
  • A Quick Ratio of 16.57 means the company can pay off $16.57 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of MaxCyte Inc:

  • The MRQ is 16.569. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 22.856. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ16.569TTM22.856-6.286
TTM22.856YOY23.327-0.471
TTM22.8565Y18.043+4.813
5Y18.04310Y18.0430.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ16.5691.587+14.982
TTM22.8561.633+21.223
YOY23.3272.185+21.142
5Y18.0432.300+15.743
10Y18.0432.255+15.788

1.4. Solvency of MaxCyte Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Maxcyte assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Maxcyte to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.13 means that Maxcyte assets are financed with 13.5% credit (debt) and the remaining percentage (100% - 13.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of MaxCyte Inc:

  • The MRQ is 0.135. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.123. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.135TTM0.123+0.012
TTM0.123YOY0.109+0.013
TTM0.1235Y0.169-0.046
5Y0.16910Y0.1690.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1350.400-0.265
TTM0.1230.386-0.263
YOY0.1090.330-0.221
5Y0.1690.440-0.271
10Y0.1690.460-0.291
1.4.2. Debt to Equity Ratio

Measures if Maxcyte is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Maxcyte to the Medical Devices industry mean.
  • A Debt to Equity ratio of 15.6% means that company has $0.16 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of MaxCyte Inc:

  • The MRQ is 0.156. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.140. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.156TTM0.140+0.016
TTM0.140YOY0.123+0.017
TTM0.1405Y0.223-0.083
5Y0.22310Y0.2230.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1560.566-0.410
TTM0.1400.569-0.429
YOY0.1230.479-0.356
5Y0.2230.626-0.403
10Y0.2230.692-0.469

2. Market Valuation of MaxCyte Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Maxcyte generates.

  • Above 15 is considered overpriced but always compare Maxcyte to the Medical Devices industry mean.
  • A PE ratio of -23.19 means the investor is paying $-23.19 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of MaxCyte Inc:

  • The EOD is -20.670. Based on the earnings, the company is expensive. -2
  • The MRQ is -23.186. Based on the earnings, the company is expensive. -2
  • The TTM is -13.403. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-20.670MRQ-23.186+2.516
MRQ-23.186TTM-13.403-9.782
TTM-13.403YOY-28.875+15.471
TTM-13.4035Y-22.808+9.404
5Y-22.80810Y-22.8080.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-20.670-1.038-19.632
MRQ-23.186-1.216-21.970
TTM-13.403-1.757-11.646
YOY-28.875-2.582-26.293
5Y-22.808-1.553-21.255
10Y-22.808-1.463-21.345
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of MaxCyte Inc:

  • The EOD is 1,630.420. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 1,828.873. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 446.660. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1,630.420MRQ1,828.873-198.452
MRQ1,828.873TTM446.660+1,382.212
TTM446.660YOY-18.714+465.374
TTM446.6605Y95.685+350.976
5Y95.68510Y95.6850.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD1,630.420-1.207+1,631.627
MRQ1,828.873-1.746+1,830.619
TTM446.660-2.961+449.621
YOY-18.714-6.143-12.571
5Y95.685-4.928+100.613
10Y95.685-5.626+101.311
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Maxcyte is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 2.11 means the investor is paying $2.11 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of MaxCyte Inc:

  • The EOD is 1.879. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.108. Based on the equity, the company is underpriced. +1
  • The TTM is 1.891. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.879MRQ2.108-0.229
MRQ2.108TTM1.891+0.217
TTM1.891YOY2.397-0.507
TTM1.8915Y1.734+0.157
5Y1.73410Y1.7340.000
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD1.8792.038-0.159
MRQ2.1082.321-0.213
TTM1.8912.444-0.553
YOY2.3973.028-0.631
5Y1.7343.918-2.184
10Y1.7344.245-2.511
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of MaxCyte Inc.

3.1. Institutions holding MaxCyte Inc

Institutions are holding 75.954% of the shares of MaxCyte Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc7.08790.000973413864533906.5823
2023-12-31Cadian Capital Management LP5.451.0569564489856448980
2023-12-31Vanguard Group Inc5.09970.000552821082432614.8277
2023-12-31Vitruvian Partners4.86926.0237504335600
2023-12-31Millennium Management LLC4.83920.01025012283116564230.3029
2023-12-31Morgan Stanley - Brokerage Accounts3.36080.001434810102155840162.684
2023-12-31FMR Inc2.73590.00128337152831312117824.0533
2023-12-31Portolan Capital Management, LLC2.6621.1331275724961358328.6231
2023-12-31Massachusetts Financial Services Company2.44950.0039253711458437229.9257
2023-09-30Holocene Advisors, LP2.04410.0289211722800
2023-12-31Geode Capital Management, LLC2.02410.00120964971230606.2358
2023-12-31State Street Corporation1.87690.000419439971038235.642
2023-12-31Blue Water Life Science Advisors, LLC1.81997.7602188500000
2023-12-31Mudita Advisors LLP1.81646.1379188134949049135.2654
2023-12-31River & Mercantile Asset Management LLP1.46621.33621518646453923.0811
2023-12-31Ameriprise Financial Inc1.39890.002144890713962910.6646
2023-12-31Granahan Investment Management Inc..1.37910.22181428449-547398-27.7045
2023-12-31ArrowMark Colorado Holdings, LLC (ArrowMark Partners)1.32630.07131373777-1035261-42.974
2023-12-31Northern Trust Corp0.76760.0007795086-2467-0.3093
2023-12-31Dimensional Fund Advisors, Inc.0.6710.00169496121835645.8149
Total 55.144723.79357117016+13227923+23.2%

3.2. Funds holding MaxCyte Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.72090.0008281825600
2024-02-29Unicorn AIM VCT Ord2.39974.8166248550000
2024-02-29iShares Russell 2000 ETF2.03650.01562109297-345-0.0164
2023-11-30IFSL Marlborough UK Micro Cap Gr A Acc1.68961.02175000000
2024-01-31MFS New Discovery I1.60980.3603166741200
2024-02-29Swedbank Robur USA A1.54480.5116160000000
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.4770.0069152980780570.5295
2023-12-31Strategic Advisers Small-Mid Cap1.2970.06871343382-502578-27.2258
2024-01-31Fidelity VIP Growth Initial1.18530.0684122770019070018.3896
2024-02-29ES R&M UK Listed Smaller Coms B Acc1.09871.2525113796300
2024-01-31Fidelity Advisor Equity Growth I1.08810.0668112705517555518.4503
2023-12-31Morgan Stanley Inst Inception I0.96651.02441001026681703213.4838
2023-12-31Morgan Stanley Inception0.9411.0057974675646703197.1824
2024-02-29MI Chelverton UK Equity Growth B Acc0.86930.5261900365-49635-5.2247
2024-01-31Columbia Small Cap Growth Inst0.86710.26289811146320.5184
2023-12-31Fidelity Small Cap Index0.84510.0162875309156471.8201
2023-07-31Amati AIM VCT Ord0.8182.1096847256-138507-14.0507
2024-02-01iShares Russell 2000 Value ETF0.73610.03357624049640.1266
2024-02-29iShares Biotechnology ETF0.68670.043711257-3200-0.4479
2023-12-31Berenberg European Micro Cap Fund M0.66380.5747687533-58618-7.8561
Total 25.54113.783426454308+971078+3.7%

3.3. Insider Transactions

Insiders are holding 1.218% of the shares of MaxCyte Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-26John Joseph JohnstonSELL50005.12
2023-12-26John Joseph JohnstonSELL50004.53
2023-12-01Douglas DoerflerSELL202005
2023-11-29Douglas DoerflerSELL53505
2023-11-27John Joseph JohnstonSELL50004.59
2023-11-14John Joseph JohnstonSELL100003.71
2023-08-30John Joseph JohnstonSELL28413.7
2023-08-28John Joseph JohnstonSELL1003.7
2023-07-26John Joseph JohnstonSELL50004.75
2023-07-12Douglas DoerflerSELL167575.02
2023-07-10Douglas DoerflerSELL4455.01
2023-06-27John Joseph JohnstonSELL74714.39
2023-06-13Douglas DoerflerSELL149685.03
2023-05-03Douglas DoerflerSELL161495.02
2023-04-12Thomas M. RossSELL55835
2023-04-11Douglas DoerflerSELL21825
2023-04-10Thomas M. RossSELL1005
2023-04-06Douglas DoerflerSELL278625.03
2023-04-05Thomas M. RossSELL69675
2023-04-04Douglas DoerflerSELL74705.03

4. Summary

4.1. Key Performance Indicators

The key performance indicators of MaxCyte Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.012-0.052+351%-0.021+85%0.149-108%0.149-108%
Book Value Per Share--2.2302.291-3%2.468-10%1.747+28%1.747+28%
Current Ratio--10.65214.064-24%15.684-32%12.342-14%12.342-14%
Debt To Asset Ratio--0.1350.123+10%0.109+23%0.169-20%0.169-20%
Debt To Equity Ratio--0.1560.140+11%0.123+27%0.223-30%0.223-30%
Dividend Per Share----0%-0%-0%-0%
Eps---0.051-0.091+80%-0.057+12%-0.057+13%-0.057+13%
Free Cash Flow Per Share--0.001-0.061+9587%-0.080+12529%-0.053+8313%-0.053+8313%
Free Cash Flow To Equity Per Share--0.005-0.056+1138%-0.073+1456%0.112-95%0.112-95%
Gross Profit Margin--2.3641.834+29%2.087+13%1.863+27%1.863+27%
Intrinsic Value_10Y_max---0.760--------
Intrinsic Value_10Y_min---0.716--------
Intrinsic Value_1Y_max---0.212--------
Intrinsic Value_1Y_min---0.208--------
Intrinsic Value_3Y_max---0.533--------
Intrinsic Value_3Y_min---0.511--------
Intrinsic Value_5Y_max---0.729--------
Intrinsic Value_5Y_min---0.686--------
Market Cap436300510.000-12%489406300.000451919860.000+8%616443680.000-21%440396250.667+11%440396250.667+11%
Net Profit Margin---0.337-0.977+190%-0.467+39%-0.639+90%-0.639+90%
Operating Margin---0.516-1.310+154%-0.634+23%-0.756+47%-0.756+47%
Operating Ratio--1.5162.310-34%1.634-7%1.757-14%1.757-14%
Pb Ratio1.879-12%2.1081.891+11%2.397-12%1.734+22%1.734+22%
Pe Ratio-20.670+11%-23.186-13.403-42%-28.875+25%-22.808-2%-22.808-2%
Price Per Share4.190-12%4.7004.340+8%5.920-21%4.229+11%4.229+11%
Price To Free Cash Flow Ratio1630.420-12%1828.873446.660+309%-18.714+101%95.685+1811%95.685+1811%
Price To Total Gains Ratio-360.728+11%-404.635-150.274-63%-646.580+60%-405.114+0%-405.114+0%
Quick Ratio--16.56922.856-28%23.327-29%18.043-8%18.043-8%
Return On Assets---0.020-0.033+67%-0.017-13%-0.038+95%-0.038+95%
Return On Equity---0.023-0.037+64%-0.019-15%-0.051+125%-0.051+125%
Total Gains Per Share---0.012-0.052+351%-0.021+85%0.149-108%0.149-108%
Usd Book Value--232167000.000238586275.000-3%256951775.000-10%181923760.000+28%181923760.000+28%
Usd Book Value Change Per Share---0.012-0.052+351%-0.021+85%0.149-108%0.149-108%
Usd Book Value Per Share--2.2302.291-3%2.468-10%1.747+28%1.747+28%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.051-0.091+80%-0.057+12%-0.057+13%-0.057+13%
Usd Free Cash Flow--66900.000-6346500.000+9587%-8315025.000+12529%-5128306.667+7766%-5128306.667+7766%
Usd Free Cash Flow Per Share--0.001-0.061+9587%-0.080+12529%-0.053+8313%-0.053+8313%
Usd Free Cash Flow To Equity Per Share--0.005-0.056+1138%-0.073+1456%0.112-95%0.112-95%
Usd Market Cap436300510.000-12%489406300.000451919860.000+8%616443680.000-21%440396250.667+11%440396250.667+11%
Usd Price Per Share4.190-12%4.7004.340+8%5.920-21%4.229+11%4.229+11%
Usd Profit---5277000.000-8906650.000+69%-4945225.000-6%-5549613.333+5%-5549613.333+5%
Usd Revenue--15666000.00010322350.000+52%11065375.000+42%9324800.000+68%9324800.000+68%
Usd Total Gains Per Share---0.012-0.052+351%-0.021+85%0.149-108%0.149-108%
 EOD+4 -4MRQTTM+23 -11YOY+19 -155Y+23 -1110Y+23 -11

4.2. Fundamental Score

Let's check the fundamental score of MaxCyte Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-20.670
Price to Book Ratio (EOD)Between0-11.879
Net Profit Margin (MRQ)Greater than0-0.337
Operating Margin (MRQ)Greater than0-0.516
Quick Ratio (MRQ)Greater than116.569
Current Ratio (MRQ)Greater than110.652
Debt to Asset Ratio (MRQ)Less than10.135
Debt to Equity Ratio (MRQ)Less than10.156
Return on Equity (MRQ)Greater than0.15-0.023
Return on Assets (MRQ)Greater than0.05-0.020
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of MaxCyte Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.442
Ma 20Greater thanMa 504.266
Ma 50Greater thanMa 1004.629
Ma 100Greater thanMa 2004.587
OpenGreater thanClose4.310
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets268,274
Total Liabilities36,107
Total Stockholder Equity232,167
 As reported
Total Liabilities 36,107
Total Stockholder Equity+ 232,167
Total Assets = 268,274

Assets

Total Assets268,274
Total Current Assets190,194
Long-term Assets78,080
Total Current Assets
Cash And Cash Equivalents 46,506
Short-term Investments 121,782
Net Receivables 5,778
Inventory 12,229
Other Current Assets 3,899
Total Current Assets  (as reported)190,194
Total Current Assets  (calculated)190,194
+/-0
Long-term Assets
Property Plant Equipment 34,754
Long Term Investments 42,938
Long-term Assets Other 388
Long-term Assets  (as reported)78,080
Long-term Assets  (calculated)78,080
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities17,855
Long-term Liabilities18,252
Total Stockholder Equity232,167
Total Current Liabilities
Short-term Debt 774
Accounts payable 743
Other Current Liabilities 11,269
Total Current Liabilities  (as reported)17,855
Total Current Liabilities  (calculated)12,786
+/- 5,069
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt17,969
Long-term Liabilities Other 283
Long-term Liabilities  (as reported)18,252
Long-term Liabilities  (calculated)18,252
+/-0
Total Stockholder Equity
Common Stock1,040
Retained Earnings -175,798
Other Stockholders Equity 406,925
Total Stockholder Equity (as reported)232,167
Total Stockholder Equity (calculated)232,167
+/-0
Other
Capital Stock1,040
Cash and Short Term Investments 168,288
Common Stock Shares Outstanding 103,703
Current Deferred Revenue5,069
Liabilities and Stockholders Equity 268,274
Net Debt -27,763
Net Invested Capital 232,167
Net Working Capital 172,339
Property Plant and Equipment Gross 45,040
Short Long Term Debt Total 18,743



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-06-302018-12-312018-06-302017-12-312017-06-302016-12-312016-06-302015-12-312015-06-302014-12-31
> Total Assets 
6,301
17,060
6,401
16,422
16,072
36,960
31,398
26,772
24,268
24,773
29,985
0
53,377
0
51,780
0
93,147
277,690
284,120
290,955
289,777
286,412
286,653
281,544
271,204
266,727
268,274
268,274266,727271,204281,544286,653286,412289,777290,955284,120277,69093,147051,780053,377029,98524,77324,26826,77231,39836,96016,07216,4226,40117,0606,301
   > Total Current Assets 
6,028
16,795
6,194
16,195
15,791
36,619
30,550
25,656
22,450
22,111
24,452
46,863
46,863
45,253
45,253
88,447
84,626
269,537
270,433
265,795
257,830
252,282
252,266
246,440
236,619
214,339
190,194
190,194214,339236,619246,440252,266252,282257,830265,795270,433269,53784,62688,44745,25345,25346,86346,86324,45222,11122,45025,65630,55036,61915,79116,1956,19416,7956,028
       Cash And Cash Equivalents 
3,409
14,279
2,412
12,181
11,727
30,163
25,342
16,022
11,248
11,469
15,211
0
38,172
0
18,755
0
37,423
58,974
47,782
239,777
109,168
43,020
11,065
37,833
54,557
49,170
46,506
46,50649,17054,55737,83311,06543,020109,168239,77747,78258,97437,423018,755038,172015,21111,46911,24816,02225,34230,16311,72712,1812,41214,2793,409
       Short-term Investments 
0
0
0
0
0
0
0
2,733
3,191
3,440
1,498
0
0
0
16,008
0
35,969
196,915
207,261
6,499
131,719
189,865
216,275
186,819
161,552
141,070
121,782
121,782141,070161,552186,819216,275189,865131,7196,499207,261196,91535,969016,0080001,4983,4403,1912,7330000000
       Net Receivables 
1,402
1,233
1,451
2,227
2,411
3,742
3,196
3,763
4,905
2,792
3,245
0
3,747
5,172
5,172
4,294
5,719
5,958
6,877
10,747
7,909
8,209
13,567
9,291
7,608
8,167
5,778
5,7788,1677,6089,29113,5678,2097,90910,7476,8775,9585,7194,2945,1725,1723,74703,2452,7924,9053,7633,1963,7422,4112,2271,4511,2331,402
       Inventory 
941
977
1,086
1,237
1,335
1,520
1,347
2,039
2,243
3,495
3,702
4,157
4,157
4,316
4,316
4,464
4,170
4,148
5,205
6,582
7,722
7,912
8,581
10,265
11,020
12,533
12,229
12,22912,53311,02010,2658,5817,9127,7226,5825,2054,1484,1704,4644,3164,3164,1574,1573,7023,4952,2432,0391,3471,5201,3351,2371,086977941
       Other Current Assets 
276
306
1,245
550
318
1,195
666
1,100
864
916
797
0
787
1,003
1,003
985
1,346
3,542
3,307
2,190
1,312
4,051
2,779
2,231
1,882
3,400
3,899
3,8993,4001,8822,2312,7794,0511,3122,1903,3073,5421,3469851,0031,00378707979168641,1006661,1953185501,245306276
   > Long-term Assets 
273
265
207
227
282
341
848
1,116
1,818
2,662
5,533
0
6,514
0
6,527
0
8,521
8,153
13,687
25,161
31,947
34,130
34,387
35,105
34,585
52,388
78,080
78,08052,38834,58535,10534,38734,13031,94725,16113,6878,1538,52106,52706,51405,5332,6621,8181,116848341282227207265273
       Property Plant Equipment 
236
202
207
227
282
341
848
1,116
1,818
2,371
5,533
6,414
6,414
6,493
6,493
6,478
6,817
7,835
13,371
24,106
31,026
32,941
33,578
34,706
33,988
33,340
34,754
34,75433,34033,98834,70633,57832,94131,02624,10613,3717,8356,8176,4786,4936,4936,4146,4145,5332,3711,8181,116848341282227207202236
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,429
42,938
42,93818,4290000000000000000000000000
       Long-term Assets Other 
37
62
0
0
0
0
0
0
0
292
0
0
100
0
34
0
1,704
318
317
1,055
921
1,190
809
399
-161,389,951
619
388
388619-161,389,9513998091,1909211,0553173181,70403401000029200000006237
> Total Liabilities 
7,948
8,420
9,484
9,354
10,989
12,153
11,801
11,419
11,986
8,694
16,384
0
16,167
0
18,555
0
14,326
13,574
21,223
28,770
32,554
31,980
32,686
33,726
30,221
33,351
36,107
36,10733,35130,22133,72632,68631,98032,55428,77021,22313,57414,326018,555016,167016,3848,69411,98611,41911,80112,15310,9899,3549,4848,4207,948
   > Total Current Liabilities 
4,279
3,264
5,091
4,245
5,652
6,784
7,240
5,837
6,573
8,379
9,343
9,166
9,166
11,614
11,614
11,432
12,534
12,577
15,618
15,548
18,107
16,763
15,427
16,639
13,205
16,649
17,855
17,85516,64913,20516,63915,42716,76318,10715,54815,61812,57712,53411,43211,61411,6149,1669,1669,3438,3796,5735,8377,2406,7845,6524,2455,0913,2644,279
       Short-term Debt 
1,552
22
822
13
14
11
854
-2,800
-2,449
0
509
0
539
0
673
0
617
572
527
480
439
152
157
475
499
699
774
7746994994751571524394805275726170673053905090-2,449-2,800854111413822221,552
       Accounts payable 
1,373
1,385
2,257
1,585
3,175
3,234
4,331
3,037
4,123
4,292
2,089
0
704
890
890
418
645
723
1,820
4,366
2,456
2,087
532
3,502
1,603
447
743
7434471,6033,5025322,0872,4564,3661,82072364541889089070402,0894,2924,1233,0374,3313,2343,1751,5852,2571,3851,373
       Other Current Liabilities 
1,354
1,856
2,012
2,646
2,463
3,539
2,055
2,800
2,449
319
3,552
0
2,850
4,843
5,209
6,067
4,518
4,956
6,524
3,871
7,902
8,232
8,025
6,913
6,411
9,918
11,269
11,2699,9186,4116,9138,0258,2327,9023,8716,5244,9564,5186,0675,2094,8432,85003,5523192,4492,8002,0553,5392,4632,6462,0121,8561,354
   > Long-term Liabilities 
3,669
5,156
4,392
5,109
5,337
5,370
4,561
5,582
5,414
315
7,041
0
7,002
0
6,940
0
1,792
997
5,605
13,222
14,446
15,216
17,260
17,086
17,017
16,702
18,252
18,25216,70217,01717,08617,26015,21614,44613,2225,6059971,79206,94007,00207,0413155,4145,5824,5615,3705,3375,1094,3925,1563,669
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
647
647
1,094
1,095
497
450
451
393
345
1,322
0
1,308
0
0
001,30801,3223453934514504971,0951,0946476470000000000000
> Total Stockholder Equity
-1,647
8,640
-3,083
7,068
5,083
24,807
19,597
15,353
12,282
16,079
13,602
0
37,210
0
33,225
0
78,821
264,116
262,897
262,185
257,223
254,432
253,967
247,819
240,983
233,377
232,167
232,167233,377240,983247,819253,967254,432257,223262,185262,897264,11678,821033,225037,210013,60216,07912,28215,35319,59724,8075,0837,068-3,0838,640-1,647
   Common Stock
19
434
20
435
435
508
509
513
513
574
574
0
766
774
774
847
847
1,004
1,012
1,015
1,017
1,019
1,024
1,029
1,031
1,036
1,040
1,0401,0361,0311,0291,0241,0191,0171,0151,0121,00484784777477476605745745135135095084354352043419
   Retained Earnings Total Equity00-159,269-148,757-137,875-133,066-126,632-118,372-114,305-109,430-106,7500000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
184,724
372,542
376,190
379,542
382,838
386,479
390,819
395,547
399,220
0
0
00399,220395,547390,819386,479382,838379,542376,190372,542184,7240000000000000000
   Treasury Stock000000000000000000000000000
   Other Stockholders Equity 
0
55,339
0
56,279
56,373
80,324
80,729
81,269
82,279
95,491
96,434
0
125,916
0
127,674
0
184,724
372,542
376,190
379,542
382,838
386,479
390,819
395,547
399,220
402,862
406,925
406,925402,862399,220395,547390,819386,479382,838379,542376,190372,542184,7240127,6740125,916096,43495,49182,27981,26980,72980,32456,37356,279055,3390



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue41,288
Cost of Revenue-8,727
Gross Profit32,56132,561
 
Operating Income (+$)
Gross Profit32,561
Operating Expense-80,776
Operating Income-48,215-48,215
 
Operating Expense (+$)
Research Development23,817
Selling General Administrative30,068
Selling And Marketing Expenses26,975
Operating Expense80,77680,860
 
Net Interest Income (+$)
Interest Income9,510
Interest Expense-0
Other Finance Cost-127
Net Interest Income9,383
 
Pretax Income (+$)
Operating Income-48,215
Net Interest Income9,383
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-37,923-58,507
EBIT - interestExpense = -48,215
-37,923
-37,923
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-48,215-37,923
Earnings Before Interest and Taxes (EBITDA)-44,044
 
After tax Income (+$)
Income Before Tax-37,923
Tax Provision-0
Net Income From Continuing Ops-37,455-37,923
Net Income-37,923
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses89,503
Total Other Income/Expenses Net10,292-9,383
 

Technical Analysis of Maxcyte
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Maxcyte. The general trend of Maxcyte is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Maxcyte's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of MaxCyte Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.61 < 4.8 < 5.29.

The bearish price targets are: 3.85 > 3.85 > 3.25.

Tweet this
MaxCyte Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of MaxCyte Inc. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

MaxCyte Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of MaxCyte Inc. The current macd is -0.06797325.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Maxcyte price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Maxcyte. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Maxcyte price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
MaxCyte Inc Daily Moving Average Convergence/Divergence (MACD) ChartMaxCyte Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of MaxCyte Inc. The current adx is 17.85.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Maxcyte shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
MaxCyte Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of MaxCyte Inc. The current sar is 4.0838143.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
MaxCyte Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of MaxCyte Inc. The current rsi is 41.44. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
MaxCyte Inc Daily Relative Strength Index (RSI) ChartMaxCyte Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of MaxCyte Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Maxcyte price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
MaxCyte Inc Daily Stochastic Oscillator ChartMaxCyte Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of MaxCyte Inc. The current cci is -18.1335626.

MaxCyte Inc Daily Commodity Channel Index (CCI) ChartMaxCyte Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of MaxCyte Inc. The current cmo is -21.0822319.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
MaxCyte Inc Daily Chande Momentum Oscillator (CMO) ChartMaxCyte Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of MaxCyte Inc. The current willr is -55.26315789.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Maxcyte is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
MaxCyte Inc Daily Williams %R ChartMaxCyte Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of MaxCyte Inc.

MaxCyte Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of MaxCyte Inc. The current atr is 0.22394185.

MaxCyte Inc Daily Average True Range (ATR) ChartMaxCyte Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of MaxCyte Inc. The current obv is 6,494,233.

MaxCyte Inc Daily On-Balance Volume (OBV) ChartMaxCyte Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of MaxCyte Inc. The current mfi is 56.44.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
MaxCyte Inc Daily Money Flow Index (MFI) ChartMaxCyte Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for MaxCyte Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-16BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-17ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-20ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.

6.3. Candlestick Patterns

MaxCyte Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of MaxCyte Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.442
Ma 20Greater thanMa 504.266
Ma 50Greater thanMa 1004.629
Ma 100Greater thanMa 2004.587
OpenGreater thanClose4.310
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Maxcyte with someone you think should read this too:
  • Are you bullish or bearish on Maxcyte? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Maxcyte? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about MaxCyte Inc

I send you an email if I find something interesting about MaxCyte Inc.


Comments

How you think about this?

Leave a comment

Stay informed about MaxCyte Inc.

Receive notifications about MaxCyte Inc in your mailbox!